Browsing Tag
Dr. Reddy’s Laboratories
68 posts
Immutep (ASX: IMM) surges 48% on FDA orphan drug designation: Is the STS pivot the new thesis?
Immutep (ASX: IMM) jumped 48% after the FDA granted orphan drug status for eftilagimod alfa in soft tissue sarcoma. Here is what the EFTISARC-NEO data means for the investment case.
Algorae Pharmaceuticals (ASX: 1AI) raises A$4m to fund dual commercial and AI drug discovery growth strategy
Algorae Pharmaceuticals (ASX: 1AI) raises A$3.99m to scale AlgoraeRx commercial portfolio and advance AlgoraeOS AI drug pipeline. Read the full strategic analysis.
Glenmark Pharmaceuticals (NSE: GLENMARK) launches GLIPIQ semaglutide in India at Rs 325 a week as generic GLP-1 era starts
Glenmark Pharmaceuticals launches GLIPIQ semaglutide in India from Rs 325 a week. Analysis of pricing, competition, and what it means for GLP-1 access. Read more.
NATCO Pharma (NSE: NATCOPHARM) launches cheapest semaglutide in India at Rs 1,290 on Day 1 of patent expiry
NATCO Pharma launches generic semaglutide in India at INR 1,290 on Day 1 of patent expiry. What it means for GLP-1 markets. Read the full analysis.
Coya Therapeutics gets FDA green light for Phase 2 ALS trial with COYA 302
Coya Therapeutics receives FDA clearance to initiate a Phase 2 trial of COYA 302 for ALS. Find out what this means for investors and the ALS drug pipeline.
Pharma stock watch: Are Indian midcaps like Glenmark better positioned than the giants?
Are Indian midcap pharma stocks like Glenmark set to outperform giants like Sun and Cipla? Explore 2025 trends, biotech bets, and market sentiment shifts.
Bloodbath on Dalal Street! 20 Indian stocks crash amid Trump tariffs, RBI rate cut and pharma panic
Discover why 20 major Indian stocks plunged on April 9, as global tariff tensions and RBI's rate cut roil investor confidence across key sectors.
Dr. Reddy’s Laboratories recalls Levetiracetam Injection in U.S. over mislabeling concerns
Dr. Reddy’s Laboratories Limited has initiated a nationwide recall of a batch of Levetiracetam in 0.75% Sodium Chloride…
Dr Reddy’s launches toripalimab in India as first immuno-oncology drug for nasopharyngeal carcinoma
Dr. Reddy’s Laboratories Ltd. announced a significant milestone in its oncology portfolio with the launch of Toripalimab in…
Dr. Reddy’s joins forces with Gilead Sciences to launch HIV drug Lenacapavir in India and 120 countries
In a historic development for HIV treatment worldwide, Dr. Reddy’s Laboratories has announced a new partnership with Gilead…